Valeant (VRX) Legal Woes Will Continue to Weigh on Stock, Including Movement in Insider Trading Suit - Wells Fargo's Maris

October 3, 2016 7:21 AM EDT
Get Alerts VRX Hot Sheet
Price: $21.96 -0.45%

Rating Summary:
    12 Buy, 11 Hold, 3 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade VRX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Wells Fargo analyst David Maris weighed in on Valeant Pharmaceuticals (NYSE: VRX), saying they continue to believe the Street is underestimating the potential downside from Valeant's many faceted legal woes.

Maris recalls there is a suit from T. Rowe Price and a separate class action suit with TIAA-CREF as the lead plaintiff, as well as investigations from the SEC, Southern District Court of NY, and IRS, among others.

"We are watching them all and have a particular interest in the insider trading suit filed against Valeant and Pershing Square related to their failed joint takeover attempt of Allergan," he commented. "Recently (9/23) we saw some action in this case, with the plaintiffs winning what is considered to be a key motion."

The analyst maintained an Underperform rating and valuation range of $17-$22.

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.

Shares of Valeant Pharmaceuticals closed at $24.55 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hedge Funds, Hot Comments, Short Sales, Trader Talk

Related Entities

William Ackman, Pershing Square Capital, Wells Fargo, David Maris

Add Your Comment